Last reviewed · How we verify
CsA-PG Ophthalmic Gel
CsA-PG is a cyclosporine A prodrug formulated as an ophthalmic gel that suppresses local immune responses in the eye to treat dry eye disease.
CsA-PG is a cyclosporine A prodrug formulated as an ophthalmic gel that suppresses local immune responses in the eye to treat dry eye disease. Used for Dry eye disease (keratoconjunctivitis sicca).
At a glance
| Generic name | CsA-PG Ophthalmic Gel |
|---|---|
| Sponsor | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Cyclosporine A is a calcineurin inhibitor that reduces T-cell activation and inflammatory cytokine production. The PG (propylene glycol) formulation enhances ocular penetration and residence time, allowing sustained immunosuppressive effects on the ocular surface to reduce inflammation and increase tear production in dry eye disease.
Approved indications
- Dry eye disease (keratoconjunctivitis sicca)
Common side effects
- Ocular irritation or burning
- Conjunctival hyperemia
- Foreign body sensation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CsA-PG Ophthalmic Gel CI brief — competitive landscape report
- CsA-PG Ophthalmic Gel updates RSS · CI watch RSS
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. portfolio CI